SG11201903846TA - 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) - Google Patents

9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Info

Publication number
SG11201903846TA
SG11201903846TA SG11201903846TA SG11201903846TA SG11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA SG 11201903846T A SG11201903846T A SG 11201903846TA
Authority
SG
Singapore
Prior art keywords
international
cabp
english
applicant
bacterial pneumonia
Prior art date
Application number
SG11201903846TA
Inventor
Evangelos L Tzanis
Paul Mcgovern
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of SG11201903846TA publication Critical patent/SG11201903846TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

T _ N T ---------- ------------- Oma dacy c line Concen tra t ion (µ g /m L) T ------ -- _ (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT omit Ill °nolo III m Oil IIII iflo oimIE (10) International Publication Number WO 2018/085216 Al (51) International Patent Classification: A61K 31/65 (2006.01) A61P 31/04 (2006.01) CO7C 237/26 (2006.01) (21) International Application Number: PCT/US2017/059165 (22) International Filing Date: 31 October 2017 (31.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/416,010 01 November 2016 (01.11.2016) US 62/422,843 16 November 2016 (16.11.2016) US 62/480,516 02 April 2017 (02.04.2017) US 62/500,611 03 May 2017 (03.05.2017) US 62/514,415 02 June 2017 (02.06.2017) US (71) Applicant: PARATEK PHARMACEUTICALS, INC. [US/US]; 75 Park Plaza, 4th Floor, Boston, MA 02116 (US). (72) Inventors: TZANIS, Evangelos L.; 3906 White Stone Road, Newtown Square, PA 19073 (US). MCGOVERN, Paul; 2176 Buttonwood Road, Berwyn, PA 19312 (US). (74) Agent: HANLEY, Elizabeth A. et al.; Mccarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: 9-AMINOMETHYL MINOCYCLINE COMPOUNDS AND USE THEREOF IN TREATING COMMUNITY-ACQUIRE BACTERIAL PNEUMONIA (CABP) Mean (± SD Concentrations of Omadacycline during the Bronchoscopy Sampling Times M -- # 1 Alveolar Cells 100 Ak---A Epithelial Lining Fluid *-6 Plasma 0.1 8 10 12 14 16 18 20 22 24 Time (hours FIG. 1-1 © (57) : The invention disclosed herein provides a method for treating Community- Acquired Bacterial Pneumonia (CABP) N using 9-[(2,2-dimethyl-propyl amino)-methyl] -minocycline or a salt thereof, in either oral or IV doses or a combination of both. [Continued on next page] C WO 2018/085216 Al MIDEDIMOMMIDEFIENIIMBEINHERVOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))
SG11201903846TA 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp) SG11201903846TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662416010P 2016-11-01 2016-11-01
US201662422843P 2016-11-16 2016-11-16
US201762480516P 2017-04-02 2017-04-02
US201762500611P 2017-05-03 2017-05-03
US201762514415P 2017-06-02 2017-06-02
PCT/US2017/059165 WO2018085216A1 (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquire bacterial pneumonia (cabp)

Publications (1)

Publication Number Publication Date
SG11201903846TA true SG11201903846TA (en) 2019-05-30

Family

ID=62076212

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201903846TA SG11201903846TA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
SG10201913599RA SG10201913599RA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913599RA SG10201913599RA (en) 2016-11-01 2017-10-31 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Country Status (13)

Country Link
US (3) US10383884B2 (en)
EP (1) EP3534908A4 (en)
JP (2) JP2019532976A (en)
CN (1) CN110087655A (en)
AU (1) AU2017353588B2 (en)
BR (1) BR112019008897A2 (en)
CA (1) CA3042514A1 (en)
MX (2) MX2019005070A (en)
PH (1) PH12019500960A1 (en)
RU (1) RU2019113715A (en)
SG (2) SG11201903846TA (en)
TW (1) TW201821082A (en)
WO (1) WO2018085216A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903846TA (en) * 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)
US20200126094A1 (en) * 2018-10-19 2020-04-23 BioIDC, Inc. Medical research fraud detection system and software
PT117254B (en) 2021-05-26 2024-04-18 Hovione Farm S A METHOD FOR SYNTHESIS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990331A (en) 1956-11-23 1961-06-27 Pfizer & Co C Stable solutions of salts of tetracyclines for parenteral administration
US2980584A (en) 1957-10-29 1961-04-18 Pfizer & Co C Parenteral magnesium oxytetracycline acetic or lactic acid carboxamide vehicle preparation
US3062717A (en) 1958-12-11 1962-11-06 Pfizer & Co C Intramuscular calcium tetracycline acetic or lactic acid carboxamide vehicle preparation
US3165531A (en) 1962-03-08 1965-01-12 Pfizer & Co C 13-substituted-6-deoxytetracyclines and process utilizing the same
US3454697A (en) 1965-06-08 1969-07-08 American Cyanamid Co Tetracycline antibiotic compositions for oral use
NL6607516A (en) 1966-05-31 1967-12-01
DE1767891C3 (en) 1968-06-28 1980-10-30 Pfizer Process for the preparation of aqueous medicinal solutions for parenteral, peroral and local use containing a tetracycline derivative
CA999855A (en) 1972-09-18 1976-11-16 Societa' Farmaceutici Italia S.P.A. Process for the preparation of tetracyclines derivatives in the 7 position
US3957980A (en) 1972-10-26 1976-05-18 Pfizer Inc. Doxycycline parenteral compositions
DE2442829A1 (en) 1974-09-06 1976-03-18 Merck Patent Gmbh TETRACYCLIC COMPOUNDS AND PROCEDURES FOR THEIR PRODUCTION
US4018889A (en) 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4126680A (en) 1977-04-27 1978-11-21 Pfizer Inc. Tetracycline antibiotic compositions
US4806529A (en) 1982-11-18 1989-02-21 Trustees Of Tufts College, Tufts University Tetracycline activity enhancement
US5589470A (en) 1990-02-26 1996-12-31 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US5064821A (en) 1982-11-18 1991-11-12 Trustees Of Tufts College Method and compositions for overcoming tetracycline resistance within living cells
US4806372A (en) 1985-02-15 1989-02-21 Georgia Oil & Gas Co., Inc. Nitrite-free-curing of bacon and product thereof
US6756365B2 (en) 1991-11-06 2004-06-29 Trustees Of Tufts College Reducing tetracycline resistance in living cells
US20020123637A1 (en) 1998-01-23 2002-09-05 Stuart B. Levy Pharmaceutically active compounds and methods of use thereof
US6256365B1 (en) 1999-08-16 2001-07-03 Analogic Corporation Apparatus and method for reconstruction of images in a computed tomography system using oblique slices
US6500812B2 (en) 1999-09-14 2002-12-31 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
US6849615B2 (en) 1999-09-14 2005-02-01 Paratek Pharmaceuticals, Inc. 13-substituted methacycline compounds
DK1240133T3 (en) 1999-09-14 2006-08-21 Tufts College Process for the preparation of substituted tetracyclines by transition metal-based chemical methods
WO2001052858A1 (en) 2000-01-24 2001-07-26 Trustees Of Tufts College Tetracycline compounds for treatment of cryptosporidium parvum related disorders
JP2004505012A (en) 2000-03-31 2004-02-19 トラスティーズ・オブ・タフツ・カレッジ 7- and 9-carbamates, ureas, thioureas, thiocarbamates, and heteroaryl-amino substituted tetracycline compounds
DE60102815D1 (en) 2000-05-15 2004-05-19 Paratek Pharm Innc 7-SUBSTITUTED CONDENSED RING TETRAZYCLINE COMPOUNDS
US20020128238A1 (en) 2000-06-16 2002-09-12 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20020132798A1 (en) 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20040224927A1 (en) 2000-06-16 2004-11-11 Trustees Of Tufts College 7-N-substituted phenyl tetracycline compounds
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
US6846939B2 (en) 2000-07-07 2005-01-25 Paratek Pharmaceuticals, Inc. 9-substituted minocycline compounds
DE60144375D1 (en) 2000-07-07 2011-05-19 Trustees Of Tufts College Medford 7-, 8-, and 9-SUBSTITUTED TETRACYCLIN COMPOUNDS
HUP0301163A3 (en) 2000-07-07 2008-08-28 Tufts College 7-substituted tetracycline dervatives, pharmaceutical compositions containing them and their use
US20050143353A1 (en) 2000-07-07 2005-06-30 Paratek Pharmaceuticals, Inc. 13-Substituted methacycline compounds
IL157860A0 (en) 2001-03-13 2004-03-28 Paratek Pharm Innc 7,9-substituted tetracycline compounds
EP1241160A1 (en) 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
AU2002250331A1 (en) 2001-03-13 2002-09-24 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
US7553828B2 (en) 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
CA2457234A1 (en) 2001-03-14 2002-09-19 Mark L. Nelson Substituted tetracycline compounds as antifungal agents
WO2002072031A2 (en) 2001-03-14 2002-09-19 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds as synergistic antifungal agents
US8088820B2 (en) 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
EP1408987B1 (en) 2001-07-13 2013-04-10 Paratek Pharmaceuticals, Inc. Tetracycline compounds having target therapeutic activities
AU2002365120A1 (en) 2001-08-02 2003-07-15 Paratek Pharmaceuticals, Inc. Medicaments
US20030069721A1 (en) 2001-09-10 2003-04-10 Paratek Pharmaceuticals, Inc. Computational method for determining oral bioavailability
EP2311798A1 (en) 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
EA200802365A1 (en) 2002-03-08 2009-08-28 Паратек Фармасьютикалс, Инк. AMINOMETHYLENE TESTING
IL164180A0 (en) 2002-03-21 2005-12-18 Paratek Pharm Innc Substituted tetracycline compounds
WO2004006850A2 (en) 2002-07-12 2004-01-22 Paratek Pharmaceuticals, Inc 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS
EP1562608A4 (en) 2002-10-24 2010-09-01 Paratek Pharm Innc Methods of using substituted tetracycline compounds to modulate rna
WO2004091513A2 (en) 2003-04-10 2004-10-28 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
US20060287283A1 (en) 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
WO2005009943A2 (en) 2003-07-09 2005-02-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2553510C (en) 2004-01-15 2012-09-25 Paratek Pharmaceuticals, Inc. Aromatic a-ring derivatives of tetracycline compounds
CA2585418A1 (en) 2004-10-25 2006-05-04 Paratek Pharmaceuticals, Inc. 4-aminotetracyclines and methods of use thereof
EP2949644A3 (en) 2004-10-25 2016-04-20 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
CA2597212A1 (en) 2005-02-04 2006-08-10 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
CA2616224A1 (en) 2005-07-21 2007-02-01 Paratek Pharmaceuticals, Inc. 10-substituted tetracyclines and methods of use thereof
WO2007087416A2 (en) 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
CA2652346A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008045507A2 (en) 2006-10-11 2008-04-17 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for treatment of bacillus anthracis infections
PT2120963T (en) 2006-12-21 2018-12-17 Paratek Pharm Innc Substituted tetracycline compounds for treatment of inflammatory skin disorders
US8318706B2 (en) 2006-12-21 2012-11-27 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP2010523684A (en) 2007-04-12 2010-07-15 パラテック ファーマシューティカルズ インコーポレイテッド Method for treating spinal muscular atrophy using a tetracycline compound
CA2688662A1 (en) 2007-04-27 2008-11-06 Paratek Pharmaceuticals, Inc. Methods for synthesizing and purifying aminoalkyl tetracycline compounds
ATE555079T1 (en) 2007-07-06 2012-05-15 Paratek Pharm Innc METHOD FOR SYNTHESIS OF 9-SUBSTITUTED MINOCYCLINE
CN102015602A (en) 2008-03-05 2011-04-13 帕拉特克药品公司 Minocycline compounds and methods of use thereof
PT2271348T (en) 2008-03-28 2018-04-16 Paratek Pharm Innc Oral tablet formulation of tetracycline compound
AU2009236631A1 (en) 2008-04-14 2009-10-22 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
TW202216656A (en) 2008-05-23 2022-05-01 美商Ｐｒｔｋ Ｓｐｖ２公司 Tosylate salts and polymorphs of a tetracycline compound
ES2558512T3 (en) 2008-08-08 2016-02-04 Tetraphase Pharmaceuticals, Inc. C7-Fluoro substituted tetracycline compounds
WO2016154332A1 (en) 2015-03-24 2016-09-29 Paratek Pharmaceuticals, Inc. Minocycline compounds for biodefense
JP7458706B2 (en) * 2016-03-24 2024-04-01 パラテック ファーマシューティカルズ，インコーポレイテッド Methods for treating and preventing Clostridium difficile infections
MX2018013271A (en) 2016-05-02 2019-03-28 Paratek Pharm Innc 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment.
TWI746610B (en) 2016-08-03 2021-11-21 美商派瑞泰Ｓｐｖ２有限公司 9-aminomethyl minocycline compounds and uses thereof
SG11201903846TA (en) * 2016-11-01 2019-05-30 Paratek Pharm Innc 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (cabp)

Also Published As

Publication number Publication date
EP3534908A1 (en) 2019-09-11
TW201821082A (en) 2018-06-16
EP3534908A4 (en) 2020-05-27
RU2019113715A3 (en) 2020-12-07
SG10201913599RA (en) 2020-02-27
JP2023058513A (en) 2023-04-25
US20200009162A1 (en) 2020-01-09
PH12019500960A1 (en) 2019-08-19
US20210052609A1 (en) 2021-02-25
RU2019113715A (en) 2020-12-03
WO2018085216A8 (en) 2018-06-21
US10835542B2 (en) 2020-11-17
JP2019532976A (en) 2019-11-14
US20180153908A1 (en) 2018-06-07
BR112019008897A2 (en) 2019-08-13
AU2017353588A1 (en) 2019-06-20
US10383884B2 (en) 2019-08-20
MX2023004966A (en) 2023-05-24
CN110087655A (en) 2019-08-02
AU2017353588B2 (en) 2022-07-14
WO2018085216A1 (en) 2018-05-11
MX2019005070A (en) 2019-09-23
CA3042514A1 (en) 2018-05-11

Similar Documents

Publication Publication Date Title
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201809082WA (en) Nlrp3 modulators
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201901658PA (en) Beta-lactamase inhibitor compounds
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201910134SA (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201809751XA (en) Egfr inhibitor compounds
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201900845YA (en) Uses of il-13 antagonists for treating atopic dermatitis
SG11201809561WA (en) 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity